Longstanding yet ever-evolving, live-attenuated, inactivated & subunit vaccines have shaped public health achievements for decades. Live-attenuated vaccines mimic natural infections, offering robust and lasting immunity with fewer doses, though they may not suit immunocompromised individuals. Inactivated formulations provide an excellent safety profile, often requiring adjuvants or booster doses to achieve sustained protection. Subunit vaccines, composed of purified antigens, present highly targeted immune stimulation while reducing the risk of adverse effects. Each of these platforms brings distinct advantages and limitations that influence their deployment in specific populations and disease settings. Innovations in genetic engineering and adjuvant science are helping to overcome historical challenges associated with stability and immunogenicity. In a world facing diverse pathogens, Live-attenuated, inactivated & subunit vaccines continue to serve as versatile tools within integrated immunization strategies worldwide.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States